Cryo-Cell International Inc (CCEL)
XASE:CCEL
Want to see CCEL full AI Analyst Report?
CCEL Stock Chart & Stats
$4.09
-$0.37(-4.74%)
At close: 4:00 PM EST
$4.09
-$0.37(-4.74%)
Day’s Range― - ―
52-Week Range$2.72 - $6.35
Previous CloseN/A
Volume3.40K
Average Volume (3M)4.07K
Market Cap
$28.19M
Enterprise Value$30.42M
Total Cash (Recent Filing)$2.90M
Total Debt (Recent Filing)$2.40M
Price to Earnings (P/E)145.3
Beta0.06
Next Earnings
Jul 10, 2026Next Dividend Ex-DateN/A
Dividend Yield11.14%
Share Statistics
EPS (TTM)-0.32
Shares Outstanding8,055,150
10 Day Avg. Volume4,683
30 Day Avg. Volume4,066
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.73
Price to Sales (P/S)1.02
P/FCF Ratio6.12
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue0.97
Enterprise Value/Gross Profit1.26
Enterprise Value/Ebitda-2.33K
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.08
Revenue Forecast (FY)$30.30M
Bulls Say, Bears Say
Bulls Say
Deferred Revenue Visibility And Estimate UpgradesAnalyst cites growing deferred revenue and recurring contracts that provide visibility into future cash flows and have prompted upward revisions to financial estimates.
High-margin Recurring RevenueAnalyst highlights that the company's core processing and storage operations generate high gross margins and mostly recurring revenue, supporting steady positive cash flow generation.
Stronger-than-expected Quarterly ResultsAnalyst reports quarterly results exceeded expectations, indicating operational resilience and potential upside to valuation assumptions.
Bears Say
Arbitration And Legal ExposureAnalyst warns that unresolved arbitration with a partner could lead to significant legal costs or an adverse ruling that would materially affect the company's financial results.
Liquidity And Funding RiskAnalyst indicates limited cash relative to debt and reliance on a credit line to fund operations, creating funding risk if litigation-related expenses rise.
Weak Revenue Growth From Specimen VolumesAnalyst notes revenue growth is under pressure because fewer new specimens are being processed, weakening confidence in the company's ability to expand its business.
Cryo-Cell International News
CCEL FAQ
What was Cryo-Cell International Inc’s price range in the past 12 months?
Cryo-Cell International Inc lowest stock price was $2.72 and its highest was $6.35 in the past 12 months.
What is Cryo-Cell International Inc’s market cap?
Cryo-Cell International Inc’s market cap is $28.19M.
When is Cryo-Cell International Inc’s upcoming earnings report date?
Cryo-Cell International Inc’s upcoming earnings report date is Jul 10, 2026 which is in 67 days.
How were Cryo-Cell International Inc’s earnings last quarter?
Cryo-Cell International Inc released its earnings results on Apr 14, 2026. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.02 by $0.03.
Is Cryo-Cell International Inc overvalued?
According to Wall Street analysts Cryo-Cell International Inc’s price is currently Overvalued.
Does Cryo-Cell International Inc pay dividends?
Cryo-Cell International Inc pays a Quarterly dividend of $0.15 which represents an annual dividend yield of 11.14%. See more information on Cryo-Cell International Inc dividends here
What is Cryo-Cell International Inc’s EPS estimate?
Cryo-Cell International Inc’s EPS estimate is 0.
How many shares outstanding does Cryo-Cell International Inc have?
Cryo-Cell International Inc has 8,055,150 shares outstanding.
What happened to Cryo-Cell International Inc’s price movement after its last earnings report?
Cryo-Cell International Inc reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.02. Following the earnings report the stock price went up 1.09%.
Which hedge fund is a major shareholder of Cryo-Cell International Inc?
Currently, no hedge funds are holding shares in CCEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cryo-Cell International Inc
Cryo-Cell International (CCEL) is a leading biotechnology company specializing in the collection, processing, and storage of stem cells derived from umbilical cord blood and tissue. Founded in 1992, CCEL operates primarily in the regenerative medicine sector, offering services that cater to families looking to preserve their newborn's stem cells for potential future medical use. The company's core offerings include private and public cord blood banking, as well as tissue banking services, which are critical for various therapeutic applications and research.
CCEL Stock 12 Month Forecast
Average Price Target
―Technical Analysis
American Shared Hospital Services
―
Concord Medical Services
―
―
DocGo
―
P3 Health Partners
―
Ownership Overview
35.70% Insiders
2.15% Mutual Funds
7.14% Other Institutional Investors
53.27% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---